[2023. 10. 26.][NYSE:CYBN]Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

 [2023. 10. 26.][NYSE:CYBN]Cybin Announces Grant of European Patent Protecting its Proprietary Deuterated Programs

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN), a trailblazing biopharmaceutical company in the field of mental healthcare, has just received a significant boost to its intellectual property portfolio with the grant of a new European patent. This patent, numbered 4,031,529, provides protection for Cybin's proprietary deuterated psilocybin analog and N, N-dimethyltryptamine (DMT) programs.

This development underscores Cybin's commitment to advancing innovative psychedelic-based treatment options for mental health conditions. The newly granted European patent covers the composition of matter for specific deuterated tryptamine compounds, including deuterated psilocybin analogs within the CYB003 program and deuterated analogs of DMT within Cybin's DMT program, as well as their medical applications.

According to Doug Drysdale, Chief Executive Officer of Cybin, "Maintaining a secure intellectual property position is fundamental to our development strategy as we continue to advance our novel molecules and optimize their therapeutic benefits." With this European patent in place, Cybin's intellectual property protection around their deuterated DMT and deuterated psilocybin programs has been significantly reinforced.

Cybin's CYB003 program, focusing on deuterated psilocybin analogs, has already completed dosing in a Phase 2 trial for major depressive disorder (MDD). Interim findings have shown that CYB003 can produce a robust psychedelic response in participants at low doses while maintaining a safe and well-tolerated therapeutic profile.

Additionally, Cybin's proprietary deuterated DMT compounds, CYB004 and SPL028, are currently undergoing Phase I clinical trials. These compounds aim to extend the DMT psychedelic experience while keeping a short-duration drug profile, potentially enabling optimized dose formulations for various administration routes and delivering distinct therapeutic benefits for patients. Preliminary results indicate that intravenous CYB004 and SPL028 elicit a psychedelic experience lasting less than 1 hour and are well-tolerated.

The company anticipates reporting topline data from its deuterated psilocybin and DMT programs in the fourth quarter of 2023.

In terms of its broader mission, Cybin seeks to transform mental healthcare by developing safe and effective psychedelic-based therapeutics for individuals suffering from mental health conditions. The company collaborates with world-class partners and esteemed scientists to advance proprietary drug discovery platforms, innovative drug delivery systems, and novel treatment regimens. Cybin's research pipeline includes investigational psychedelic-based compounds such as CYB003 and CYB004.

With its headquarters in Canada and operations spanning across several countries, including the United States, the United Kingdom, the Netherlands, and Ireland, Cybin is poised to make a meaningful impact in the mental healthcare landscape.